Placement Agent on Helix Acquisition Corp. II's Private Placement Financing
Oppenheimer & Co. Inc. acted as Placement Agent on Helix Acquisition Corp. II’s $260MM Private Placement Financing in connection to the Business Combination with BridgeBio Oncology Therapeutics (BBOT)
TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (BBOT), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, and Helix Acquisition Corp. II (Nasdaq: HLXB), a special purpose acquisition company (SPAC) sponsored by Cormorant Asset Management, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, the company will be renamed “BridgeBio Oncology Therapeutics.” The combined company’s common stock is expected to be listed on Nasdaq under the ticker symbol BBOT.
In addition to approximately $196 million held in Helix Acquisition Corp. II’s trust account (assumed as of the closing and assuming no redemptions by Helix’s public shareholders), the transaction also includes commitments for an approximately $260 million PIPE from a group of premier institutional investors.
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
2025 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 7691770.1